MedTrace Logo

Xanthohumol and Metabolic Syndrome

NCT01367431 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2015-07-24

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetics (PK) of xanthohumol (XN). Small amounts of xanthohumol occur naturally in hops, used to make beer, and XN is also found in beer itself. Studies in animals have shown that XN can lower blood sugar and blood lipids such as triglycerides, which can contribute to heart disease. The purpose of this study is to see how much of the XN is absorbed into the blood and how fast it leaves the body when taken by mouth. Once the PK study has been done, the investigators' long-term goal is to learn if xanthohumol can lower risk factors for heart disease and type-2 diabetes in humans.

Conditions

  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Xanthohumol

PK study with one capsule of one of the three doses randomly assigned

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Oregon State University

    lead OTHER

Principal Investigators

  • Jan F Stevens, PhD · Oregon State University

  • Jon Q Purnell, MD · Oregon Health and Science University

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01367431 on ClinicalTrials.gov